Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
Recent Articles
RELATED ARTICLES
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
Innovent ditches low-value stake sale after investor outcry
1801.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
Discover hidden China stock gems in our weekly newsletter